A. et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343–5352 (2011). Article CAS PubMed PubMed Central Google Scholar Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation...
Also called cell-transfer therapy, it is one of a new class of approaches being developed to strengthen the innate ability of the immune system to fight cancer
This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.doi:10.1097/00002371-200411000-00028Wang, Li-XinShu, SuyuPlautz, GregoryJournal of Immunotherapy
Clinical ImmunotherapeuticsTheresa L.Whiteside, Ronald B.Herberman. (1994) Adoptive Immunotherapy of Cancer. Clinical Immunotherapeutics 2 , 13-22 /Resenberg SA: Adoptive immunotherapyof cancer: accom- plishments and prospects. Cancer Treat Rep 68:233-255, 1984...
otherapy for Cancer Adoptive T Cell Immunotherapy for CancerAdoptive T Cell Immunotherapy for CancerScienceOpenRambam Maimonides Medical Journal
Adoptive immunotherapy for cancer: building on success. Adoptive cell transfer after host preconditioning by lymphodepletion represents an important advance in cancer immunotherapy. Here, we describe how a lymph... L Gattinoni,DJ Powell,SA Rosenberg,... - 《Nature Reviews Immunology》 被引量: 1717...
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously ... BG...
In addition, current status of adoptive cell transfer using other T cell populations for cancer immunotherapy that may circumvent some of the problems related to current protocols of using CTL is also discussed.doi:10.2174/157339408783565475Li Zhang, Pouneh Dokouhaki...
γδ T cells can be an option for adoptive immunotherapy of cancer. The major obstacle to clinical application of γδ T cells is their low number and lack of a reliable method to expand them consistently and efficiently. We were able to expand γδ T cells with high purity in all donors...
We assessed the efficacy and safety of adoptive immunotherapy administered to 17 patients with TaGIII or recurrent TaGII superficial bladder cancer following transurethral tumor resection. Macrophage activated killer (MAK) cells were obtained from autologous mononuclear cells harvested by apheresis, after in...